Clinical Trial

QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)

Name: QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD) — clinical trial record (NCT07113964)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study will evaluate the safety and efficacy of QL1706 and Olaparib in human epidermal growth factor receptor 2 (HER2)-negative unresectable and/or metastatic breast cancer who had received 2-4 line of prior systematic therapy.

Trial Details

NCT Number	NCT07113964
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University
Conditions	Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency
Enrollment	79 participants
Start Date	2025-08-30
Primary Completion	2027-03-30 (estimated)
Study Completion	2029-03-30 (estimated)
Updated on ClinicalTrials.gov	2025-08-11